Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Human C5 Nanobody (SAA1365)

Catalog #:   RHB90002 Specific References (26) DATASHEET
Host species: Alpaca
Isotype: VHH-8His-Cys-tag
Applications: BIF, ELISA
Expression system: Mammalian Cells
Overview

Catalog No.

RHB90002

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Alpaca

Isotype

VHH-8His-Cys-tag

Clonality

Monoclonal

Target

CPAMD4, C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, Complement C5

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P01031

Applications

BIF, ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1365

Data Image
  • SDS-PAGE
    SDS PAGE for Human C5 Nanobody
References

Differences in complement activation of serum-resistant and serum-sensitive Klebsiella pneumoniae isolates., PMID:40424786

A new treatment for canine B-cell lymphoma based on a recombinant single-domain antibody immunotoxin derived from Pseudomonas aeruginosa exotoxin A., PMID:40256602

GRP78 Nanobody-Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy., PMID:40135833

Expression Analysis of Heavy-Chain-Only Antibodies in Cloudy Catshark and Japanese Bullhead Shark., PMID:39852530

C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis., PMID:39798960

Characteristics and Genomic Localization of Nurse Shark (Ginglymostoma cirratum) IgNAR., PMID:39684588

Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant., PMID:39675603

Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: A Single-Center Experience., PMID:39596538

Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration., PMID:38142486

The solution structure of the heavy chain-only C5-Fc nanobody reveals exposed variable regions that are optimal for COVID-19 antigen interactions., PMID:37838175

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies., PMID:37356719

Rabbit derived VL single-domains as promising scaffolds to generate antibody-drug conjugates., PMID:36964198

VH-Based Mini Q-Body: A Novel Quench-Based Immunosensor., PMID:36850849

Structure determination of an unstable macromolecular complex enabled by nanobody-peptide bridging., PMID:36173177

Structure-Guided Engineering of a Complement Component C3-Binding Nanobody Improves Specificity and Adds Cofactor Activity., PMID:35935935

[The frontline of TMA management]., PMID:35662172

Multifaceted Activities of Seven Nanobodies against Complement C4b., PMID:35428691

Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective., PMID:34643472

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19., PMID:34552091

Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies., PMID:33671302

A Complement C3-Specific Nanobody for Modulation of the Alternative Cascade Identifies the C-Terminal Domain of C3b as Functional in C5 Convertase Activity., PMID:32938727

An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase., PMID:32769120

A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system., PMID:32376685

A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein., PMID:30555486

Introducing site-specific cysteines into nanobodies for mercury labelling allows de novo phasing of their crystal structures., PMID:28994409

Specific detection of foot-and-mouth disease serotype Asia 1 virus by carboxyl-magnetic beads conjugated with single-domain antibody., PMID:26369792

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human C5 Nanobody (SAA1365) [RHB90002]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only